This site is intended for healthcare professionals

The FDA will convene an Advisory Committee meeting to review the NDA for roxadustat to treat anemia of CKD. - AstraZeneca + FIbroGen Inc.

Read time: 1 mins
Last updated:2nd Mar 2021
Published:3rd Mar 2021
Condition: Anaemia and CKD
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest